Invivyd (IVVD) Income from Continuing Operations (2021 - 2025)
Invivyd posted quarterly Income from Continuing Operations of 12555000.0 for Q4 2025, up 34.71% year-on-year from 9320159.63 in Q4 2024, and down 13.9% on a QoQ basis from 11023000.0 in Q3 2025.
Invivyd (IVVD) has 5 years of Income from Continuing Operations data on file, last reported at 12555000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 34.71% year-over-year to 12555000.0; the trailing twelve-month figure through Dec 2025 stood at 55560000.0 (up 68.59% YoY), and the FY2025 full-year result was 55560000.0, up 68.59% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 12555000.0, down from 11023000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11023000.0 in Q3 2025 and bottomed at 100739000.0 in Q1 2022.
- The 5-year median for Income from Continuing Operations is 46710000.0 (2022), against an average of 46003100.0.
- The widest annual swing landed in 2022, when Income from Continuing Operations slumped 160.25%; it then soared 82.31% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 83090000.0 in 2021, then jumped by 41.98% to 48212000.0 in 2022, then slumped by 59.2% to 76752000.0 in 2023, then jumped by 74.95% to 19229000.0 in 2024, then jumped by 34.71% to 12555000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 12555000.0 (Q4 2025), 11023000.0 (Q3 2025), and 15060000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | -12.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.56 Mn |
| Sep 30, 2025 | -11.02 Mn |
| Jun 30, 2025 | -15.06 Mn |
| Mar 31, 2025 | -16.92 Mn |
| Dec 31, 2024 | -19.23 Mn |
| Sep 30, 2024 | -62.31 Mn |
| Jun 30, 2024 | -49.25 Mn |
| Mar 31, 2024 | -46.09 Mn |
| Dec 31, 2023 | -76.75 Mn |
| Sep 30, 2023 | -43.06 Mn |
| Jun 30, 2023 | -53.88 Mn |
| Mar 31, 2023 | -39.07 Mn |
| Dec 31, 2022 | -48.21 Mn |
| Sep 30, 2022 | -47.33 Mn |
| Jun 30, 2022 | -51.75 Mn |
| Mar 31, 2022 | -100.74 Mn |
| Dec 31, 2021 | -83.09 Mn |
| Sep 30, 2021 | -60.37 Mn |
| Jun 30, 2021 | -44.67 Mn |
| Mar 31, 2021 | -38.71 Mn |